bluuebunny/crossref_metadata_2025_split huggingface dataset:
1606. Legionellosis Cluster Associated with Direct and Indirect Hot Tub Exposure—West Virginia, 2018
Authors: Rispens Jared R , Edens Chris , Barskey Albert , Mercante Jeffrey , Ritter Troy , Martin Stephen B , Hast Marisa , Siegel Miriam , Thomasson Erica , Huff Jackie L , Baker Carolyne A , Everly Chelsea 
Published: October 2019

Abstract

Background
In October 2018, the West Virginia Bureau for Public Health (BPH) notified CDC of one Legionella urinary antigen test (UAT)-positive case of Legionnaires’ disease (LD) in a worker at a racetrack facility. Following investigation by BPH and the county health department, five additional LD cases were identified among facility workers within a one-month period. Our objective was to determine the extent of the outbreak and identify potential sources of exposure.

Methods
We interviewed the previously identified patients and conducted case-finding among racetrack workers. Our case definitions included confirmed LD (pneumonia with a positive UAT), suspected LD (pneumonia without a UAT completed), and Pontiac fever (PF) (self-limited, nonspecific flu-like symptoms) among employees with exposure to the facility within 14 days prior to symptom onset. We conducted an environmental assessment of the facility and the surrounding area for sources of potential Legionella exposure.

Results
We identified 17 cases (71% in men, 35% in current smokers, median age 55 years): six confirmed LD, four suspected LD, and seven suspected PF cases. Our environmental assessment revealed a poorly maintained hot tub in the first floor jockey area. All samples collected from the hot tub (which was chlorinated before our arrival) tested negative for Legionella. Two employees with confirmed LD (33%), three with suspected LD (75%), and six with suspected PF (86%) had direct exposure to the hot tub or adjacent hallway; the remaining six were exposed only to a second floor office suite. Further investigation identified deficiencies in the facility’s ventilation systems and a crack in the floor between the hot tub and office areas. These factors created a pathway for Legionella-containing aerosols from the hot tub to pass into the second floor office space and air-handling unit for recirculation to occupied areas.

Conclusion
Our investigation suggests that both direct and indirect exposure to a Legionella reservoir can cause illness. This finding supports analysis of ventilation systems and airflow dynamics in future LD outbreak investigations. Clinicians should consider LD in pneumonia patients with direct or indirect exposure to suspected Legionella sources to ensure appropriate testing and treatment.

Disclosures
All authors: No reported disclosures.
1620. Effectiveness of the 2016 California Policy Eliminating Non-Medical Exemptions on Vaccine Coverage: A Synthetic Control Analysis
Authors: Nyathi Sindiso , Karpel Hannah , Sainani Kristin L , Maldonado Yvonne , Hotez Peter J , Bendavid Eran , Lo Nathan C 
Published: October 2019

Abstract

Background
Vaccine hesitancy in low vaccine coverage “hot spots” has led to recent outbreaks of vaccine-preventable diseases across the United States. State policies to improve vaccine coverage by restricting non-medical (personal belief) exemptions are heavily debated and their effectiveness is unclear due to limited rigorous policy analysis. In 2016, a California policy (SB 277) eliminated non-medical exemptions from kindergarten requirements. To address the ongoing debate on such policies, we performed a quasi-experimental, controlled analysis of the policy’s impact on vaccine and exemption outcomes.

Methods
We used state vaccine coverage and exemption data (2011–2017) from the CDC and health data from public sources. We prespecified a primary outcome of MMR coverage (%) and secondary outcomes of medical and non-medical exemptions (%). We included covariates related to socioeconomic and health measures (e.g., insurance, well child visits) and pre-2016 mean coverage. Using the synthetic control method, with 2016 as the treatment year and a 2-year post-policy period, we constructed a “control” California, from a weighted sum of states. We used permutation testing to repeat the process for each of the other states and their unique synthetic control, to determine whether there was a meaningful difference in California (i.e., a change in California’s coverage relative to its control in the top 5th percentile of states). We tested the model’s sensitivity to various analytical assumptions.

Results
Of 43 control states, synthetic California was predominantly comprised of Idaho, Mississippi, and Arkansas, and had a good pre-policy match on outcomes. MMR coverage in California increased by 3.2% relative to synthetic California in the post period (Top 1 of 44 states, Figure 1). Medical exemptions increased by 0.4%, while non-medical exemptions decreased by 2.2% in the post-period (Top 1 of 43 states). The model was robust to changes in covariates and control states.

Conclusion
The policy resulted in a meaningful increase in MMR coverage and reduction in non-medical exemptions. We measured a modest increase in medical exemptions, but this was offset by the larger reduction in non-medical exemptions. State policies removing non-medical exemptions can be effective in increasing vaccination coverage.

Disclosures
All authors: No reported disclosures.
1656. Klebsiella pneumoniae Antimicrobial Susceptibility to Carbapenems in Latin America Between 2000 and 2014
Authors: Sati Hatim , Bruinsma Nienke , Hsieh Jenny , Galas Marcelo F , Ramon-Pardo Pilar 
Published: October 2019

Abstract

Background
Antimicrobial resistance (AMR) to carbapenems in Enterobacteriaceae such as Klebsiella pneumoniae (KPN) is a major global public health concern. Infections caused by these pathogens are associated with high morbidity and mortality and perpetuated by limited safe alternative treatment options. This study aims to describe the antimicrobial susceptibility patterns amongst KPN to the carbapenems Latin America.

Methods
Surveillance laboratory data from 2000 to 2014 were obtained through the ReLAVRA network from 19 countries in Latin America. Longitudinal trends of mean percentage non-susceptibility for the region were conducted and evaluated with a significance level of P < 0.05.

Results
A total of 209,972 and 181,128 KPN isolates were reported from 2000 to 2014 for antibiotic susceptibility to imipenem and meropenem, respectively. From 2000 to 2014 an increasing trend was observed in the reported % KPN NS to imipenem (P < 0.0001) from 0.6% to 11.6% with an average annual percentage increase (AAPI) of 36.3% [95% CI: 39.8%–33%]. (Figure 1). Similarly, the % KPN NS to meropenem increased (P < 0.0001) from 0% in 2000 to 12.3% in 2014 with an AAPI of 49.5% [95% CI: 54%–44.6%] (Figure 2). For both antibiotics, the last 5 years of the timeframe (2010 to 2014) showed the highest rate of increase in NS. NS to carbapenems varied significantly between reporting countries, with the highest % KPN NS to imipenem and meropenem reported by Brazil, Guatemala, Nicaragua, and Peru.

Conclusion
The increase in KPN NS to carbapenems observed in Latin America threatens effective treatment of infections caused by this pathogen. The extremely limited treatment options could lead to further increases in morbidity and mortality. Strengthening health systems and core country capacity to identify and deal with these emerging high-risk pathogens and resistance mechanisms, through surveillance is vital to inform public health actions, control measures, mitigate outbreaks and support further development of Public health actions against AMR at country and regional level.

Disclosures
All authors: No reported disclosures.
1690. Risk Factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
Authors: Kunawathanakul Sithichai , Meesing Atibordee , Foocharoen Chingching 
Published: October 2019

Abstract

Background
Invasive aspergillosis (IA) has been reported in systemic lupus erythematosus (SLE) patients. We assessed the risk factors of invasive aspergillosis in SLE patients.

Methods
A retrospective age- and sex-matched case–control study with ratio 3:1 in adult SLE patients from January 2002- December 2017 at Srinagarind Hospital, Khon Kaen University, KhonKaen, Thailand has been conducted. We excluded the patients who were overlap with other immunocompromised condition.

Results
Of 1,585 SLE patients, 22 patients (1.4%) had invasive aspergillosis and 66 controls were included in the study. The mean age was 36.9 ± 11.8 years and 76 (86.4%) patients were female. SLE patients who developed IA had statistically significant lower median total absolute lymphocyte count than control (503 vs. 1342 cells/mm3, P = 0.05) and history of steroid treatment (adjusted OR 21.43, P = 0.006) were the risk factor of IA.

Conclusion
There was a low prevalence of IA in SLE patients. Low total lymphocyte count, renal impairment and history of steroid treatment were significantly associated with invasive aspergillosis in SLE patients.

Disclosures
All authors: No reported disclosures.
1691. Cryptococcus Species Other than C. neoformans and C. gattii: Are They Clinically Significant?
Authors: Cano Cevallos Edison J , Yetmar Zachary A , Razonable Raymund R 
Published: October 2019

Abstract

Background
Cryptococcus sp. is a major cause of opportunistic infections in immunocompromised patients, with nearly all cases due to C. neoformans or C. gattii. There are occasional reports of other Cryptococcus species causing invasive human disease. However, their epidemiology and clinical significance are not fully defined. We sought to describe the patients with cultures positive for Cryptococcus species other than neoformans and gattii.

Methods
A retrospective descriptive review of patients with cultures growing Cryptococcus species other than neoformans and gattii from November 2011 to February 2019. Clinical and laboratory data were analyzed.

Results
Out of 177 cases with a culture positive for Cryptococcus sp., 54 patients (mean age, 53.3 years; 61% men) had a culture for Cryptococcus other than neoformans and gattii. The most common species were unspecified non-neoformans/gattii (10), magnus (9), laurentii (8), and ater (7). Three patients had active malignancies and 15 were on immunosuppressive drugs, 6 due to transplant. The most common sites or specimens were skin (16), respiratory (16), urine (7), joint (3), intravascular catheter (2), cerebrospinal fluid (2), oral (2), peritoneal fluid, donor liver transplant, bone marrow, sinus, nail, and cornea. Whereas 21 (38.9%) cultures were obtained due to local symptoms, there was only one case of invasive disease, affecting the peritoneum, while the majority was either unaddressed (25) or considered contaminants (17). Only 12 patients received antifungal treatment, where sources were skin (4), oral (2), peritoneum, donor liver, respiratory, vascular catheter, urine, and nail. Antifungal drugs were fluconazole, itraconazole, clotrimazole, caspofungin, and griseofulvin, for a mean duration of 37.6 days. Among patients who were not treated, four died within 6 months but mostly of unrelated causes (3) or not known (1).

Conclusion
This large series of patients with Cryptococcus sp. other than neoformans and gattii suggests that these species rarely cause clinically significant infection in humans. Only one case of invasive disease was found.

Disclosures
All authors: No reported disclosures.
1707. Invasive Pulmonary Aspergillosis in Patients with Severe Fever with Thrombocytopenia Syndrome
Authors: Bae Seongman , Jung Jiwon , Jae Kim Min , Cho Eunbeen , Young Kim Mi , Yun Sung-Cheol , Hwa Lee Keun , Pil Chong Yong , Lee Sang-Oh , Choi Sang-Ho , Soo Kim Yang , Hee Woo Jun , Kim Sung-Han 
Published: October 2019

Abstract

Background
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease often accompanied by immune catastrophic course and subsequent fatal outcome. More than 90% of patients with SFTS had leukopenia and about one-third of those need the admission of intensive care unit (ICU) during the hospital course. So, there has been growing concern about the complications such as invasive pulmonary aspergillosis (IPA) in critical SFTS patients. We thus investigate the incidence and clinical characteristics of IPA in patients with SFTS.

Methods
All patients who were confirmed as SFTS in a tertiary care hospital, Seoul, South Korea, between January 2013 and October 2018 were enrolled. The modified AspICU algorithm was used to identify cases of putative invasive pulmonary aspergillosis (PIPA) and discriminate these invasive diseases from colonization.

Results
Of the 45 PCR-confirmed SFTS patients, 16 (36%) received ICU care. Of these 16 patients, 9 (56%) developed PIPA during hospitalization. The median duration from admission to the first evidence of PIPA was 8 days (range, 2–11 days). None of the PIPA cases met the revised EORTC/MSG criterion. Septic shock and corticosteroid administration preceded more frequently in PIPA group than non-PIPA group (100% vs. 19%, P < 0.0001 and 67% vs. 14%, P = 0.003, respectively). Patients complicated by PIPA showed significantly higher mortality than non-PIPA patients (44% vs. 8%, P = 0.048 by log-rank test). Mortality was lower in patients with PIPA who received antifungal treatment (17% [1/6]) than in those with PIPA who did not (100% [3/3]) (log-rank test, P = 0.002).

Conclusion
More than half of patients with SFTS in ICU were complicated by IPA during early hospital course. Cautious scrutiny for IPA in patients with SFTS followed by early appropriate antifungal therapy for IPA is needed.

Disclosures
All authors: No reported disclosures.
1709. Epidemiology of Invasive Fungal Infection (IFI) after Severe Influenza Requiring Intensive Care Unit (ICU) Admission: 10-Year Experience at a Tertiary Care Center in the United States
Authors: Viehman J Alex , Sappington Penny , McCreary Erin K , Marini Rachel V , Shields Ryan K , Rivosecchi Ryan , Clarke Lloyd , Clancy Cornelius J , Nguyen Minh-Hong 
Published: October 2019

Abstract

Background
Despite increasing recognition of aspergillosis complicating severe influenza and its associated high fatality in Europe, incidence and features of the disease in the United States are unknown.

Methods
We reviewed all influenza cases requiring ICU admission from 2009 to 2019 at our center.

Results
262 patients with influenza required ICU admission. 4% (10) developed IFI at median 2d after influenza diagnosis. 80% (8/10) of patients with IFI were infected with influenza A vs. 88% (221/252) without IFI. 20% were on steroids at the time of IFI diagnosis. 70% of IFI required mechanical ventilation. Types of IFI were pneumonia (70%, 6 Aspergillus and 1 Wangiella), endobronchial IFI (20%, 1 each with Aspergillus and Lictheimia), and Coccidioides fungemia (10%). 4% (10) of patients were fungal colonized, but did not have IFI (5 A. fumigatus, 1 A. terreus, 4 Penicillium). CT findings of IFI included nodules (4), cavitation (3), and ground-glass opacities (2). Serum galactomannan (GM) was positive in 3 (43%). Median time to antifungal therapy (AF) was 2 days. Triazoles were prescribed to all 7 patients with aspergillosis. Posaconazole and amphotericin B were AF for patients with Wangiellaand Lichteimia, respectively. Patients with C. immitis fungemia died before AF. Median duration of AF was 60 days among survivors. Patients with IFI required acute hemodialysis more frequently than colonized patients (60% vs. 0%, P = 0.01). 30-day mortality was 60% (6/10) and 20% 92/10) in patients with IFI and colonization, respectively (P = 0.2). Patients with IFI had significantly higher in-hospital and 60-day mortality than those without IFI (Fig 1, P = 0.009).

Conclusion
Our rate of post-influenza IFI (4%) was lower than reported in Europe (~15%), which might stem from a lack of systematic BAL GM testing at our center, over-reliance on GM to make diagnoses in Europe, and/or differences in pt populations and clinical practices in treating severe influenza. IFI and fungal colonization rates were similar at our center, highlighting the importance of using well-defined criteria to define disease. Given the high mortality of post-influenza IFI, priority should be given to defining risk factors that might identify patients for targeted AF prophylaxis. In using AF, it is important to recognize that Aspergillus is not the only cause of IFI.

Disclosures
All authors: No reported disclosures.
1745. Retrospective Cohort Analysis to Determine the Incidence of CMV Infection and Disease in Allogeneic Hematopoietic Cell Transplant Recipients at an Academic Children’s Hospital
Authors: Galetaki Despoina M , Hayes Molly , Newman Alexander , Boge Craig L K , Elgarten Caitlin W , Freedman Jason L , Olson Timothy S , Fisher Brian T 
Published: October 2019

Abstract

Background
Data on cytomegalovirus (CMV) infection and disease by donor (D)/recipient (R) status or prophylaxis regimen in pediatric hematopoietic cell transplant (HCT) recipients are limited. There is an absence of data on adverse events (AE) attributable to prophylaxis.

Methods
A single-center cohort (N = 352) of allogeneic HCT episodes between January 2004 and June 2017 was assembled. Exclusion criteria were CMV PCR positivity 30 days before HCT, lack of CMV surveillance (<2 blood PCRs in the 30 days post HCT), or unknown D/R CMV status. CMV prophylaxis was recommended for CMV D+ or R+ patients with ≥1 of the following factors: T-cell depletion, cord blood product, or exposure to distal alemtuzumab. The CMV prophylaxis regimen was standard-dose acyclovir from day −7 to +7, then foscarnet to engraftment, and then valganciclovir to day +100 (acyc → fos → valgan). If a patient did not meet criteria for CMV prophylaxis but was HSV IgG positive then standard-dose acyclovir was given from day −7 to the end of study follow-up (SD-acyc). All remaining patients did not receive antiviral prophylaxis. Outcomes of CMV infection and CMV disease by day +180 were captured. AEs attributable to antiviral prophylaxis were also identified. An AE was attributed to an antiviral prophylaxis medication if the dose was reduced or stopped. AEs were only reported in HCT episodes with complete medical records (n = 221).

Results
The CMV infection rate was 26.7%, with a median time to detection of 23.5 days (range: 4–146). CMV infection was common in D+/R+ (58.9%) and D−/R+ (34.6%) patients. Just under 11% of CMV infections progressed to disease (Figures 1 and 2). Breakthrough CMV infection occurred in 49.1% of patients despite acyc → fos → valgan (Figure 3) at a median of 11 days from HCT (range: 4–132). The attributable AE rate was 13.4% and 36.8% for SD-acyc and acyc → fos → valgan, respectively (Figure 4).

Conclusion
CMV infection was common in D+/R+ and D−/R+ patients, and a substantial proportion progressed to disease. Breakthrough infection persisted despite acyc → fos → valgan prophylaxis and AEs attributable to this regimen were common. CMV infection in R+ patients was frequent even in the absence of additional risk factors. Studies of novel prophylaxis approaches are needed and should include R+ patients regardless of other factors.

Disclosures
All authors: No reported disclosures.
1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
Authors: Danino Dana , Stanek Joseph , Skeens Micah , Rangarajan Hemalatha , Ardura Monica I 
Published: October 2019

Abstract

Background
Allo-HCT recipients are at increased risk for vaccine-preventable infections. Early vaccination (EV) beginning at 3–6 months (mo) post-HCT has been shown to be safe, immunogenic, and is recommended. We assessed adherence and immunogenicity to EV in children post-allo-HCT.

Methods
Retrospective analysis of allo-HCT performed 1/1/10–6/30/18 at NCH. Children who died, relapsed, or received anti-CD20 biologics in the 6 mo preceding intended vaccination were excluded. Institutional guidelines recommend EV starting at 6 (+1) mo post-HCT with: 3 PCV13 + 1 PPSV23, IPV, HBV, DTaP and HIB. Vaccination rates were analyzed at 6(+1), 8(+1) and 10(+1) mo post-HCT and serologies were obtained pre- and ≥ 4 weeks post vaccination. Immunogenicity was defined as antibody (Ab) concentrations ≥ 1.3 µg/mL or a 4 fold rise ≥ 70% of 10 PCV13 serotypes, tetanus (T) and diphtheria (D) Ab ≥ 0.1 IU/mL, and HBs Ab ≥ 10 IU/mL. Non-parametric statistics were applied; correlations between T&B cell subsets and IgG pre-vaccination and specific Ab post-vaccination were performed.

Results
During the 8-year study period, 171 allo-HCT were performed: 131 children were eligible for EV (Table 1); however, EV occurred in only 49.6% (65/131) and was completed in 37.5% (45/120) of children at 10(+1) mo post-HCT. Vaccine immunogenicity of PCV13, HBV, T and D was achieved in 40/45, 34/36, 63/64, and 18/18 of evaluable children, respectively. Protective Ab response after EV for PCV13, HBV, T and D was found in 21/24 (87.5%), 14/16 (87.5%), 35/36 (97.2%), and 8/8 (100%) children, respectively. Specific IgG geometric mean concentration pre- and post-vaccination was similar in children whether they received early or delayed vaccination (median 9.8 mo post-HCT, IQR 8–14) (Figures 1 and 2). No correlations were found between absolute CD4, CD8, CD19 and IgG pre-vaccination and vaccines specific Abs post-vaccination (Figure 3).

Conclusion
Despite recommendations, adherence to EV was low among our cohort of allo-HCT recipients and identified opportunities for improvement. Overall, vaccines were immunogenic with no significant differences in Ab concentrations among patients receiving early vs. delayed vaccination. No robust correlations were found between number of T&B cells or total IgG and Ab titers.

Disclosures
All authors: No reported disclosures.